These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32112872)

  • 21. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease.
    Bhatia HS; Bailey J; Unlu O; Hoffman K; Kim RJ
    Pacing Clin Electrophysiol; 2019 Nov; 42(11):1463-1470. PubMed ID: 31599969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rivaroxaban's Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis.
    Coleman CI; Kreutz R; Sood N; Bunz TJ; Meinecke AK; Eriksson D; Baker WL
    Clin Appl Thromb Hemost; 2019; 25():1076029619868535. PubMed ID: 31392894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin.
    Alberts M; Chen YW; Lin JH; Kogan E; Twyman K; Milentijevic D
    Stroke; 2020 Feb; 51(2):549-555. PubMed ID: 31888412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
    Lip GY; Keshishian A; Kamble S; Pan X; Mardekian J; Horblyuk R; Hamilton M
    Thromb Haemost; 2016 Oct; 116(5):975-986. PubMed ID: 27538358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
    Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.
    Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
    Clin Ther; 2015 Mar; 37(3):554-62. PubMed ID: 25749196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US).
    Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
    Adv Ther; 2021 Jul; 38(7):3771-3788. PubMed ID: 34031859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
    Palamaner Subash Shantha G; Bhave PD; Girotra S; Hodgson-Zingman D; Mazur A; Giudici M; Chrischilles E; Vaughan Sarrazin MS
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28408716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.
    Baker CL; Dhamane AD; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Menges B; Lin J; Nadkarni A
    Adv Ther; 2019 Jan; 36(1):162-174. PubMed ID: 30499067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis.
    Costa OS; O'Donnell B; Vardar B; Abdelgawwad K; Brescia CW; Sood N; Coleman CI
    Curr Med Res Opin; 2021 Sep; 37(9):1493-1500. PubMed ID: 34166150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting.
    Mahajan D; Wu B; Song J; Milentijevic D; Ashton V; Mittal VS
    Drugs Aging; 2020 Apr; 37(4):281-289. PubMed ID: 32147804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
    Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
    Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy.
    Alberts MJ; He J; Kharat A; Ashton V
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):425-436. PubMed ID: 35092000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
    Bansal VK; Herzog CA; Sarnak MJ; Choi MJ; Mehta R; Jaar BG; Rocco MV; Kramer H
    Am J Kidney Dis; 2017 Dec; 70(6):859-868. PubMed ID: 28941763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China.
    Liu L; Hong D; Ma K; Lu X
    J Clin Pharm Ther; 2021 Jun; 46(3):658-668. PubMed ID: 33226144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of Outcomes of Treatment With Oral Anticoagulants in Patients With Atrial Fibrillation and Multiple Chronic Conditions: A Comparative Effectiveness Analysis.
    Mentias A; Shantha G; Chaudhury P; Vaughan Sarrazin MS
    JAMA Netw Open; 2018 Sep; 1(5):e182870. PubMed ID: 30646182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.